Cure Alveolar Soft Part Sarcoma International (iCureASPS)

Very intriguing article from Japan researchers that performed a study to identify proteins aberrantly regulated in ASPS. They found that the expression of 145 proteins differed significantly. Among them, further investigation was focused on the SET oncogene, which has multifunctional roles in cancers. Immunohistochemistry confirmed overexpression of SET in all 15 ASPS cases examined. SET is known to be an inhibitor of phosphatase 2A (PP2A), which functions as a tumor suppressor by inhibiting the signal tranduction pathway and inducing apoptosis. We found that a PP2A activator, FYN720, which is used for treatment of multiple sclerosis, decreased cell proliferation through apoptosis. Together, our findings may suggest the possible contribution of SET to the progression of ASPS, and the utility of the PP2A activator, FYN720, for treatment of ASPS.
The source:
Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma.
http://www.ncbi.nlm.nih.gov/pubmed/24621013
I hope that clinical trials would follow.

Olga

Thanks so much for the article
Beings that cancer causes an autoimmune like response and that MS is an autoimmune disease , it will be interesting to see if the drug for MS will be useful on ASPS.

Found a simple article on cancer and proteins so I could even begin to familiarize myself with your above article
I am still working my way through the above article 12 hours later

http://www.mskcc.org/blog/recently-reve ... rug-design

Deb